Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
11 aug 2009 - 07:32
Statutaire naam
Crucell N.V.
Titel
Crucell Announces Second Quarter 2009 Results
Bericht
Total revenues and other operating income of €78.7 million,
an increase of 32% compared to Q2 2008.
Gross margin 39%, up from 36% in Q2 2008.
Operating profit of €3.2 million versus operating loss of €9.01 million in Q2 2008.
2009 full year guidance reiterated: total revenues and other operating income
expected to grow 20% in constant currencies2; operating profit for 2009 expected
to improve significantly compared to 2008; solid cash flow.
Leiden, the Netherlands (August 11, 2009) – Dutch biopharmaceutical
company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today
announced its financial results for the second quarter of 2009, based on
International Financial Reporting Standards (IFRS). These financial results are
unaudited.
Datum laatste update: 27 juli 2024